ImmuCell Corporation (ICCC)

From the record

ImmuCell Corporation's filings since 2017 show 4 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2017-08-22); a warning not to rely on past financial statements (8-K item 4.02, the latest 2022-11-10); an auditor change (8-K item 4.01, the latest 2019-04-12); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2022-11-10) (its current reports).

From the record

ImmuCell Corporation's 4 filed years say what it did: revenue went from $19 million in fiscal 2022 to $28 million in fiscal 2025, up 14.2% a year; it rose in 2 of 3 years; the deepest fall was 6% from fiscal 2022 to fiscal 2023; net income was positive in 0 of 4 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, ImmuCell Corporation lost about 4 cents for every dollar of shareholders' money, and gross profitability: its products earned about 27 cents per dollar of everything the company owns. Leverage: it owed about 36 cents per dollar of assets, and net share issuance: its share count grew 10.5% over the year (the filed statements).

From the record

ImmuCell Corporation's standing among 17 graded names in its industry family: revenue of $28 million in fiscal 2025 ranks in the top 50% by size; a net margin of -3.8% ranks in the top 26%; revenue growth of 14.2% a year over the last 3 filed years ranks in the top 28% (its annual reports).

From the record

ImmuCell Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Te, Boekhorst Paul Francis Olivier (President and CEO, as filed), filing under that title since 2025-11-07, 1 years (bottom 21% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 4.4 years (bottom 46%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (bottom 37%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

ImmuCell Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $4 million against debt of $9 million leaves -12.4% of its assets as net cash, bottom 19% of its family; cash from operations less capital spending is 4.4% of revenue (top 16%); a gross margin of 41.4% (bottom 38%); research spending of 11% of revenue (bottom 41%) (its annual report).

From the record

ImmuCell Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 14.2% a year over the last three filed years against 14.2% over all 4, speeding up (top 37% of its family); the newest year grew 4.3% (top 44%); research spending grew -12.2% a year (bottom 32%); capital spending grew -32% a year (bottom 43%) (its annual reports). ImmuCell Corporation reported 2 lines of business in fiscal 2024: Scours at $26 million, Mastitis at $179 thousand. 2 of 2 grew in the latest filed year, and the largest line is 99% of revenue (its annual report).

From the record

ImmuCell Corporation's newest year against its own record: revenue of $28 million in fiscal 2025 came in 12.6% below the $32 million its prior three years' pace pointed to (bottom 37% of its family); net income of $1 million against a prior three-year average of $3 million (top 9%); a net margin of -3.8% against -18.2% before (bottom 47%) (its annual reports).